PDL BIOPHARMA, INC. (31)
Browse by Contract Category
Contracts
-
Commercial Sublease Agreement dated as of November 5, 2020 by and between RDH Investments LLC and the Company
(Filed With SEC on November 13, 2020)
-
Asset Transfer Agreement dated as of August 11, 2020 between Defined Diagnostics, LLC (F/K/A Wellstat Diagnostics LLC) and the
(Filed With SEC on November 13, 2020)
-
Settlement and Mutual Release Agreement among the Company, Samuel J. Wohlstadter, Nadine H. Wohlstadter, Hyperion Catalysis International, Wellstat Vaccines, LLC, Wellstat Immuno...
(Filed With SEC on November 13, 2020)
-
Transition Services Agreement, dated as of September 30, 2020, between PDL BioPharma, Inc. and LENSAR, Inc
(Filed With SEC on October 2, 2020)
-
Share Purchase Agreement between Bartleby Limited and the Company, dated as of July 30, 2020
(Filed With SEC on August 10, 2020)
-
Tax Matters Agreement, dated as of September 30, 2020, between PDL BioPharma, Inc. and LENSAR, Inc
(Filed With SEC on October 2, 2020)
-
Separation and Distribution Agreement, dated as of September 30, 2020, by and between PDL BioPharma, Inc
(Filed With SEC on October 2, 2020)
-
Confidential Severance Agreement and Release of All Claims
(Filed With SEC on August 20, 2020)
-
2020 Annual Bonus Plan
(Filed With SEC on May 11, 2020)
-
Form of Stock Option Grant Notice Supplement
(Filed With SEC on March 11, 2020)
-
Wind Down Retention Plan effective as of December 21, 2019
(Filed With SEC on March 11, 2020)
-
Form of Inducement Restricted Stock Agreement (Amended 11/15/19)
(Filed With SEC on March 11, 2020)
-
Form of Nonstatutory Inducement Stock Option Grant Notice Supplement
(Filed With SEC on March 11, 2020)
-
Form of Nonstatutory Inducement Stock Option Agreement (Amended 11/15/19)
(Filed With SEC on March 11, 2020)
-
Form of Stock Option Agreement Amendment Acknowledgment
(Filed With SEC on March 11, 2020)
-
Fifth Amendment to Lease Agreement between Mountain Bluebird Investments, LLC and the Company, effective November 11, 2019
(Filed With SEC on March 11, 2020)
-
Description of Registrants Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934
(Filed With SEC on March 11, 2020)
-
Severance Plan adopted as of November 15, 2019
(Filed With SEC on March 11, 2020)
-
Form of Restricted Stock Agreement (Amended 11/15/19)
(Filed With SEC on March 11, 2020)
-
Form of Restricted Stock Agreement Amendment Acknowledgment
(Filed With SEC on March 11, 2020)
-
Form of Stock Option Agreement (Amended 11/15/19)
(Filed With SEC on March 11, 2020)
-
Cooperation and Support Agreement, dated as of February 27, 2020, by and among PDL BioPharma, Inc., Engine Capital, L.P. and its affiliates
(Filed With SEC on February 28, 2020)
-
Supplemental Indenture, dated September 17, 2019 by and between PDL BioPharma, Inc., as Issuer and The Bank of New York Mellon Trust Company, N.A., as Trustee
(Filed With SEC on September 17, 2019)
-
Indenture, dated September 17, 2019, between PDL, BioPharma, Inc., as Issuer and The Bank of New York Mellon Trust Company, N.A., as Trustee
(Filed With SEC on September 17, 2019)
-
Form of Exchange Agreement
(Filed With SEC on September 13, 2019)
-
Confidential Severance Agreement and Release of All Claims
(Filed With SEC on August 19, 2019)
-
Noden Settlement Letter and Supply Agreement Amendment
(Filed With SEC on August 7, 2019)
-
Offer Letter between the Company and Ed Imbrogno
(Filed With SEC on June 24, 2019)
-
2019 Annual Bonus Plan
(Filed With SEC on May 9, 2019)
-
Securities Purchase Agreement
(Filed With SEC on April 11, 2019)
-
Executive Severance Plan and Schedule of Benefits
(Filed With SEC on April 10, 2019)
